Inhaled insulin is effective for controlling blood sugar levels in children with diabetes, providing them with a ...

Hims and Hers announced this morning that it will begin offering compounded semaglutide (generic Ozempic or Wegovy) for $199 ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Africa's diabetes market is set to grow 7.2% annually, reaching $2.73 billion by 2025. Key trends include expanding CGM access, supporting local prod ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Stay Informed On Tariff Changes, Macroeconomic Trends, And More.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, June 30, 2025 /EINPresswire.com/ -- How Big Is The Global ...

Suzhou-based Innovent Biologics secured approval last week for its treatment mazdutide. Read more at straitstimes.com. Read ...

Novo Nordisk A/S and Eli Lilly & Co ... and safe as weekly injections peddled by Novo and Lilly. Leading insulin producer Gan & Lee Pharmaceutical is pushing ahead a longer-acting drug that can be ...

On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development.

Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly ...

Novo Nordisk launches its first GLP-1 product, liraglutide, branded as Victoza in 2009 in Europe and in 2010 in the U.S. In 2013, Novo Nordisk's semaglutide starts global phase 3 trials.

Novo Nordisk's booming obesity drugs & diabetes portfolio make it a top growth play. Click here to read an analysis of NVO stock now.